Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma

Abstract Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcom...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masahiro Yoshida, Yosuke Nakaya, Katsujun Shimizu, Naoko Tatsumi, Minako Tsutsumi, Hoyuri Fuseya, Mirei Horiuchi, Takuro Yoshimura, Yoshiki Hayashi, Takafumi Nakao, Takeshi Inoue, Takahisa Yamane
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4bc35587960143248af35001577f9702
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4bc35587960143248af35001577f9702
record_format	dspace
spelling	oai:doaj.org-article:4bc35587960143248af35001577f97022021-12-02T10:44:21ZImportance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma10.1038/s41598-021-82615-42045-2322https://doaj.org/article/4bc35587960143248af35001577f97022021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82615-4https://doaj.org/toc/2045-2322Abstract Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0–22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment.Masahiro YoshidaYosuke NakayaKatsujun ShimizuNaoko TatsumiMinako TsutsumiHoyuri FuseyaMirei HoriuchiTakuro YoshimuraYoshiki HayashiTakafumi NakaoTakeshi InoueTakahisa YamaneNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Masahiro Yoshida Yosuke Nakaya Katsujun Shimizu Naoko Tatsumi Minako Tsutsumi Hoyuri Fuseya Mirei Horiuchi Takuro Yoshimura Yoshiki Hayashi Takafumi Nakao Takeshi Inoue Takahisa Yamane Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
description	Abstract Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0–22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment.
format	article
author	Masahiro Yoshida Yosuke Nakaya Katsujun Shimizu Naoko Tatsumi Minako Tsutsumi Hoyuri Fuseya Mirei Horiuchi Takuro Yoshimura Yoshiki Hayashi Takafumi Nakao Takeshi Inoue Takahisa Yamane
author_facet	Masahiro Yoshida Yosuke Nakaya Katsujun Shimizu Naoko Tatsumi Minako Tsutsumi Hoyuri Fuseya Mirei Horiuchi Takuro Yoshimura Yoshiki Hayashi Takafumi Nakao Takeshi Inoue Takahisa Yamane
author_sort	Masahiro Yoshida
title	Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
title_short	Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
title_full	Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
title_fullStr	Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
title_full_unstemmed	Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
title_sort	importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large b-cell lymphoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4bc35587960143248af35001577f9702
work_keys_str_mv	AT masahiroyoshida importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT yosukenakaya importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT katsujunshimizu importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT naokotatsumi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT minakotsutsumi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT hoyurifuseya importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT mireihoriuchi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takuroyoshimura importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT yoshikihayashi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takafuminakao importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takeshiinoue importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takahisayamane importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma
_version_	1718396760489984000

Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma

Ejemplares similares